Annual CFF
$21.44 M
+$9.99 M+87.19%
December 31, 2023
Summary
- As of February 7, 2025, RDHL annual cash flow from financing activities is $21.44 million, with the most recent change of +$9.99 million (+87.19%) on December 31, 2023.
- During the last 3 years, RDHL annual CFF has fallen by -$62.93 million (-74.59%).
- RDHL annual CFF is now -74.59% below its all-time high of $84.37 million, reached on December 31, 2020.
Performance
RDHL Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
N/A
June 1, 2024
Summary
- RDHL quarterly cash flow from financing activities is not available.
Performance
RDHL Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFF
N/A
June 1, 2024
Summary
- RDHL TTM cash flow from financing activities is not available.
Performance
RDHL TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RDHL Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +87.2% | - | - |
| 3 y3 years | -74.6% | - | - |
| 5 y5 years | -48.7% | - | - |
RDHL Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -70.8% | +87.2% | ||||
| 5 y | 5-year | -74.6% | +87.2% | ||||
| alltime | all time | -74.6% | +840.3% |
RedHill Biopharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $21.44 M(+87.2%) | - | - |
| Jun 2023 | - | $3000.00(-99.9%) | $6.29 M(-70.3%) |
| Mar 2023 | - | $4.81 M(-33.2%) | $21.21 M(+85.2%) |
| Dec 2022 | $11.45 M(-84.4%) | $7.20 M(-225.9%) | $11.45 M(-47.5%) |
| Sep 2022 | - | -$5.72 M(-138.4%) | $21.82 M(-17.8%) |
| Jun 2022 | - | $14.92 M(-401.7%) | $26.54 M(+169.3%) |
| Mar 2022 | - | -$4.94 M(-128.1%) | $9.86 M(-86.6%) |
| Dec 2021 | $73.46 M(-12.9%) | $17.57 M(-1855.4%) | $73.46 M(+15.1%) |
| Sep 2021 | - | -$1.00 M(-43.4%) | $63.83 M(-16.9%) |
| Jun 2021 | - | -$1.77 M(-103.0%) | $76.79 M(-8.5%) |
| Mar 2021 | - | $58.66 M(+638.6%) | $83.95 M(-0.5%) |
| Dec 2020 | $84.37 M(+137.6%) | $7.94 M(-33.6%) | $84.37 M(-25.0%) |
| Sep 2020 | - | $11.96 M(+121.9%) | $112.53 M(+12.1%) |
| Jun 2020 | - | $5.39 M(-90.9%) | $100.37 M(+5.9%) |
| Mar 2020 | - | $59.08 M(+63.7%) | $94.78 M(+166.9%) |
| Dec 2019 | $35.51 M(-15.0%) | $36.10 M(<-9900.0%) | $35.51 M(+99.9%) |
| Sep 2019 | - | -$206.00 K(+3.5%) | $17.77 M(-57.2%) |
| Jun 2019 | - | -$199.00 K(+7.0%) | $41.52 M(-0.5%) |
| Mar 2019 | - | -$186.00 K(-101.0%) | $41.72 M(-0.1%) |
| Dec 2018 | $41.76 M(+62.8%) | $18.36 M(-22.1%) | $41.76 M(-5.8%) |
| Sep 2018 | - | $23.55 M(>+9900.0%) | $44.34 M(+113.0%) |
| Jun 2018 | - | $0.00(-100.0%) | $20.82 M(-0.8%) |
| Mar 2018 | - | -$145.00 K(-100.7%) | $20.99 M(-18.2%) |
| Dec 2017 | $25.65 M | $20.93 M(>+9900.0%) | $25.65 M(-36.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | $30.00 K(-82.9%) | $40.63 M(+0.1%) |
| Jun 2017 | - | $175.00 K(-96.1%) | $40.60 M(+0.2%) |
| Mar 2017 | - | $4.51 M(-87.4%) | $40.52 M(+12.5%) |
| Dec 2016 | $36.02 M(-34.3%) | $35.91 M(>+9900.0%) | $36.02 M(>+9900.0%) |
| Sep 2016 | - | $0.00(-100.0%) | $144.00 K(-99.7%) |
| Jun 2016 | - | $100.00 K(+900.0%) | $41.67 M(+0.2%) |
| Mar 2016 | - | $10.00 K(-70.6%) | $41.60 M(-24.1%) |
| Dec 2015 | $54.79 M(+124.8%) | $34.00 K(-99.9%) | $54.79 M(+0.1%) |
| Sep 2015 | - | $41.52 M(>+9900.0%) | $54.76 M(+313.3%) |
| Jun 2015 | - | $36.00 K(-99.7%) | $13.25 M(-3.6%) |
| Mar 2015 | - | $13.20 M(>+9900.0%) | $13.74 M(-43.6%) |
| Dec 2014 | $24.37 M(+968.8%) | $0.00(-100.0%) | $24.37 M(-3.3%) |
| Sep 2014 | - | $14.00 K(-97.3%) | $25.20 M(-4.8%) |
| Jun 2014 | - | $527.00 K(-97.8%) | $26.46 M(+1.8%) |
| Mar 2014 | - | $23.83 M(+2750.2%) | $25.99 M(+1040.0%) |
| Dec 2013 | $2.28 M(-65.2%) | $836.00 K(-34.2%) | $2.28 M(-70.4%) |
| Sep 2013 | - | $1.27 M(+2091.4%) | $7.69 M(+14.9%) |
| Jun 2013 | - | $58.00 K(-49.6%) | $6.70 M(+0.5%) |
| Mar 2013 | - | $115.00 K(-98.2%) | $6.67 M(+1.8%) |
| Dec 2012 | $6.55 M(-52.7%) | $6.25 M(+2172.0%) | $6.55 M(+2068.9%) |
| Sep 2012 | - | $275.00 K(+918.5%) | $302.00 K(+1018.5%) |
| Jun 2012 | - | $27.00 K(>+9900.0%) | $27.00 K(>+9900.0%) |
| Mar 2012 | - | $0.00 | $0.00 |
| Dec 2011 | $13.84 M(+24.8%) | - | - |
| Dec 2010 | $11.09 M | - | - |
FAQ
- What is RedHill Biopharma annual cash flow from financing activities?
- What is the all time high annual CFF for RedHill Biopharma?
- What is RedHill Biopharma annual CFF year-on-year change?
- What is the all time high quarterly CFF for RedHill Biopharma?
- What is the all time high TTM CFF for RedHill Biopharma?
What is RedHill Biopharma annual cash flow from financing activities?
The current annual CFF of RDHL is $21.44 M
What is the all time high annual CFF for RedHill Biopharma?
RedHill Biopharma all-time high annual cash flow from financing activities is $84.37 M
What is RedHill Biopharma annual CFF year-on-year change?
Over the past year, RDHL annual cash flow from financing activities has changed by +$9.99 M (+87.19%)
What is the all time high quarterly CFF for RedHill Biopharma?
RedHill Biopharma all-time high quarterly cash flow from financing activities is $59.08 M
What is the all time high TTM CFF for RedHill Biopharma?
RedHill Biopharma all-time high TTM cash flow from financing activities is $112.53 M